Irritable bowel syndrome (IBS) affects approximately one tenth of the general population and is characterized by abdominal pain associated with abnormalities in bowel habits. Visceral hypersensitivity, abnormal intestinal motor function, mucosal immune activation, and increased intestinal permeability concur to its pathophysiology. Psychological factors can influence symptom perception at the central nervous system level. In addition, recent evidence suggests that dysbiosis may be a key pathophysiological factor in patients with IBS. Increasing understanding of the pathophysiological mechanisms translates into new and more effective therapeutic approaches. Indeed, in line with this evidence, IBS therapies nowadays include agents able to modulate gut microbiota function and composition, such as diet, prebiotics, probiotics, and antibiotics. In addition, in the last decade, an increasing interest in fecal microbiota transplantation has been paid. An in-depth understanding of the intestinal microenvironment through accurate faucal microbiota and metabolite analysis may provide valuable insights into the pathophysiology of IBS, finally shaping new tailored IBS therapies.

Gut microbiota signatures and modulation in irritable bowel syndrome / Marasco, Giovanni; Cremon, Cesare; Barbaro, Maria Raffaella; Stanghellini, Vincenzo; Barbara, Giovanni. - In: MICROBIOME RESEARCH REPORTS. - ISSN 2771-5965. - ELETTRONICO. - 2022:(2022), pp. 0-11. [10.20517/mrr.2021.12]

Gut microbiota signatures and modulation in irritable bowel syndrome

Marasco, Giovanni;Barbaro, Maria Raffaella;Stanghellini, Vincenzo;Barbara, Giovanni
2022

Abstract

Irritable bowel syndrome (IBS) affects approximately one tenth of the general population and is characterized by abdominal pain associated with abnormalities in bowel habits. Visceral hypersensitivity, abnormal intestinal motor function, mucosal immune activation, and increased intestinal permeability concur to its pathophysiology. Psychological factors can influence symptom perception at the central nervous system level. In addition, recent evidence suggests that dysbiosis may be a key pathophysiological factor in patients with IBS. Increasing understanding of the pathophysiological mechanisms translates into new and more effective therapeutic approaches. Indeed, in line with this evidence, IBS therapies nowadays include agents able to modulate gut microbiota function and composition, such as diet, prebiotics, probiotics, and antibiotics. In addition, in the last decade, an increasing interest in fecal microbiota transplantation has been paid. An in-depth understanding of the intestinal microenvironment through accurate faucal microbiota and metabolite analysis may provide valuable insights into the pathophysiology of IBS, finally shaping new tailored IBS therapies.
2022
Gut microbiota signatures and modulation in irritable bowel syndrome / Marasco, Giovanni; Cremon, Cesare; Barbaro, Maria Raffaella; Stanghellini, Vincenzo; Barbara, Giovanni. - In: MICROBIOME RESEARCH REPORTS. - ISSN 2771-5965. - ELETTRONICO. - 2022:(2022), pp. 0-11. [10.20517/mrr.2021.12]
Marasco, Giovanni; Cremon, Cesare; Barbaro, Maria Raffaella; Stanghellini, Vincenzo; Barbara, Giovanni
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/912792
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact